棕榈酸帕利哌酮对急性期精神分裂症患者疗效、安全性及社会功能的影响被引量：18

Effects of palmitate paripadone in the treatment of patients with acute schizophrenia on the efficacy,safety and social function

暂未订购

导出

摘要目的探讨棕榈酸帕利哌酮治疗急性期精神分裂症患者疗效、安全性及其对社会功能的影响。方法将符合ICD-10诊断标准的32例首发或复发的急性期精神分裂症患者给予肌注棕榈酸帕利哌酮注射液,分别在基线及治疗后第2、5、9、13周末进行阳性和阴性综合征量表(PANSS)、个人和社会功能量表(PSP)及治疗中需处理的不良反应症状量表(TESS)评定。结果患者自治疗后第2周末始PANSS总分及各因子分较基线均有所改善(P<0.05),自第5周末始PSP评分较基线均有所改善(P<0.05)。且随着治疗时间延长,患者精神症状及社会功能改善更显著。药物总不良反应发生率为43.75%,但未见严重不良反应。结论棕榈酸帕利哌酮注射液起效迅速,可有效改善急性期精神分裂症患者精神症状及社会功能,且安全性高。 Objective To explore the efficacy,safety and social function of paliperidin palmitate in the treatment of acute schizophrenia. Methods 32 patients with first-episode or recurrent acute schizophrenia who met the ICD-10 diagnostic criteria were given intramuscular paliperidone palmitate injection. The Positive and Negative Syndrome Scale（ PANSS）,the Personal and Social Function Scale（ PSP） and the Treatment Emergent Symptom Scale（ TESS） were rated at baseline,2 nd,5 th,9 th,and13 th. Results The PANSS total scores and factor scores improved from baseline in the second week of the study（ P〈0. 05）,and the PSP scores improved from baseline at the end of the 5 th（ P〈0. 05）. With the extension of treatment time,the patient＇s mental symptoms and social function improved more significantly. The overall drug adverse reaction rate was 43. 75%,but no serious adverse reactions were seen. Conclusion The paliperidone palmitate injection has a rapid effect and high safety,and can effectively improve the psychiatric symptoms and social function of patients with acute schizophrenia.

作者刘洁白录东 LIU Jie;BAI Ludong(Shandong Mental Health Center Jinan 250014,China)

机构地区山东省精神卫生中心

出处《精神医学杂志》 2018年第1期42-44,共3页 Journal of Psychiatry

基金山东省医药卫生科技发展计划(编号:2017WS792)

关键词棕榈酸帕利哌酮注射液精神分裂症安全性社会功能 Palmitate paripadone Schizophrenia Safety Social function

分类号 R749.3 [医药卫生—神经病学与精神病学]

引文网络
相关文献

参考文献2

1雷彤,孙凌,李玄.帕利哌酮注射液与利培酮治疗精神分裂症的对照研究[J].天津药学,2015,27(3):33-36. 被引量：3
2白汉平,阳前军,张俊成.棕榈酸帕利哌酮治疗大学生精神分裂症40例[J].医药导报,2015,34(4):483-486. 被引量：10

二级参考文献35

1EMSLEY R, OOSTHUIZEN P, KOEN L, et al. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone longacting injection [J]. Int Clin Psychopharmacol, 2008 , 23 (6): 325-331.
2NUSSBAUM AM, STROUP T S. Paliperidone palmitate for schizophrenia [J]. Cochrane Library ,2012,3 (6) :69-72.
3LIEBERMAN J A, STROUP T S, MCEUOY J P, et al. Eff- ectiveness of antipsychotic drugs in patients with chronic schizophrenia [J]. N Engl J Med, 2005 , 353 ( 12) : 1209 - 1223.
4MCEVOY J P, LIEBERMAN J A, PERKINS D 0, et al. Efficacy and tolerability of olanzapine , quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison [J]. Am J Psychiatry ,2007,164(7) : 1050-1060.
5SABATE E. Adherence to long-term therapies: evidence for action [Z]. Geneva, Switzerland: W orId Health Organization, 2003.
6NEWTON R,HUSTIG H,LAKSHMANA R,et al. Practical guidelines on the use of paliperidone palmitate in schizophrenia[J] . CUff Med Res Opin , 2012,28 ( 4) : 559- 567.
7CHUE P, CHUE J. A review of paliperidone palmitate [J] . Expert Rev. Neurother,2012,12(12) :1383-1397.
8PEUSKENS J, RUBIO G, SCHREINER A. Dosing and switching of paliperidone ER in patients with schizophrenia: recommendations for clinical practice [J]. Ann Gen Psychiatry ,2014,13 (1) : 10.
9LEUCHT C,HERES S,KANE J M,et al. Oral versus depot antipsychotic dTIlgs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials[J]. Schizophr Res,2011 ,127( 1-3) :83-92.
10TAKEUCHI K, SANJO K, SAKAI A. Paliperidone, risperidone[J]. Nihon Rinsho,2013,71 (4) :654-659.